Atlas Venture Associates IX, L.P. is 10% Owner at Intellia Therapeutics, Inc. (NTLA). They have made 2 open-market trades across 1 company since 2017, most recently 2017-07-10.
CIK 0001671208
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
0 open-market purchases, against 2 sales. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| NTLA | 3,659,788 | $41.8M |
Shares reported on the most recent Form 4, priced at the 2017-07-11 close.
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.